Your institution may have rights to this item. Sign in to continue.
Title
Reply: Appropriate prospective trials are warranted to determine differences between exon 19 deletions and L858R EGFR mutations in non-small cell lung cancer.
A response by H. Asahina, K. Yamazaki, and I. Kinoshita to a letter to the editor about their article on the progression and survival of non-small cell lung cancer patients with exon 19 deletions.